Clinical Trial

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT: NCT06274801 · RECRUITING

NCT IDNCT06274801

StatusRECRUITING

Start Date2024-09-03

SponsorGossamer Bio USA, Inc. (INDUSTRY)

First posted2024-02-23

Last updated2026-10-13

Brief Summary

This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.